1,026 Experimental treatments in acute stroke

Annals of Neurology

Volumn 59, Issue 3, 2006, Pages 467-477

  O'Collins, Victoria E ^a   Macleod, Malcolm R ^c   Donnan, Geoffrey A ^b   Horky, Laura L ^b   Van Der Worp, Bart H ^d   Howells, David W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2,4,6,7 TETRAMETHYL 2 [(4 PHENYL 1 PIPERIDINYL)METHYL] 5 BENZOFURANAMINE; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 3,3 BIS(3 FLUOROPHENYL) N METHYLPROPYLAMINE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; ABCIXIMAB; APTIGANEL; ARUNDIC ACID; ATENOLOL; BACLOFEN; BATROXOBIN; CANDESARTAN; CANDESARTAN HEXETIL; CLOMETHIAZOLE; CROBENETINE; DANAPAROID; DARODIPINE; DEXTRORPHAN; DIAZEPAM; DISUFENTON SODIUM; EBSELEN; ELIPRODIL; EPTIFIBATIDE; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FOSPHENYTOIN SODIUM; GAVESTINEL; GINKGO BILOBA EXTRACT; GLYCINE; LACTACYSTIN BETA LACTONE; LANICEMINE; LDP 01; LIFARIZINE; LUBELUZOLE; MAGNESIUM SULFATE; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; NALMEFENE; NALOXONE; NEUROPROTECTIVE AGENT; NICERGOLINE; NORPHENAZONE; NOVOCEBRIN; NS 1209; PROPENTOFYLLINE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; REMACEMIDE; REPINOTAN; ROVELIZUMAB; S 1746; SIPATRIGINE; TINOFEDRINE; TIRILAZAD; TIROFIBAN; TRAXOPRODIL; TRAZODONE; TSUKUBAENOLIDE; UK 279276; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINOL NICOTINATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HISTOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; STROKE; STROKE THERAPY ACADEMY INDUSTRY ROUNDTABLE CRITERIA; TREATMENT OUTCOME;

ANIMALS; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; META-ANALYSIS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PUBMED; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33644818304     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20741     Document Type: Article

References (28)

1. Pound P, Ebrahim S, Sandercock P, et al. Where is the evidence that animal research benefits humans? Br Med J 2004;328:514-517.
2. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-2136.
3. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx. 2004;1:36-45.
4. Green AR, Odergren T, Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci Vol. 2003;24:402-408.
5. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002;33:306-307.
6. Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs Vol. 2001;15:165-174.
7. Del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow. J Intern Med 1995;237:79-88.
8. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004;35:1203-1208.
9. Macleod MR, O'Collins T, Horky EL, et al. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005;25:713-721.
10. Van der Worp HB, De Haan P, Morrema E, Kalkman CJ. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J Neurol 2005;2525:1108-1114.
11. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
12. Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular penumbras after focal cerebral ischemia [review]. J Cereb Blood Flow Metab. 2000;20:1011-1032.
13. Heiss W-D, Thiel A, Grond M, Graf R. Which targets are relevant for therapy acute ischemic stroke? Stroke 1999;30:1486-1489.
14. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-1568.
15. Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol Sci 1998;19:59-66.
16. Cochrane Central Register of Controlled Trials (CENTRAL). 2005. The Cochrane Collaboration, John Wiley & Sons, Ltd.
17. Stroke Center. Clinical trials directory. Online: http://www. strokecenter.org. 2005.
18. Sharma SS. Emerging neuroprotective approaches in stroke treatment. Current Research & Information on Pharmaceutical Sciences 2003;4:8-12.
19. Labiche LA, Grotta JC. Clinical trials for cytoprotection in Stroke. NeuroRx 2004;1:46-70.
20. Nagai N, Vanlinthout I, Collen D. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 1999;100:2541-2546.
21. Huang R, Zeng J, Pei Z. [Effects of defibrinogenase on photochemically induced middle cerebral artery occlusion in stroke-prone renovascular hypertensive rats]. Zhonghua Yi Xue Za Zhi 1999;79:711-713.
22. Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol 1992;215:265-269.
23. Numagami Y, Sato S, Ohnishi ST. Attenuation of rat ischemic brain damage by aged garlic extracts: a possible protecting mechanism as antioxidants. Neurochem Int 1996;29:135-143.
24. Buchan AM, Gertler SZ, Li H, et al. A selective N-type Ca(2+)-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab 1994;14:903-910.
25. AstraZeneca. First results from SAINT I trial show AstraZeneca's Cerovine (NXY-059) demonstrates a reduction in disability in patients with acute ischemic stroke. http://www.astrazeneca.com/pressrelease/4979.aspx, 2005.
26. Macleod MR, O'Collins T, Horky LL, et al. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005;38:35-41.
27. Meng W, Wang X, Asahi M, et al. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1999;19:1316-1321.
28. WHO. The World Health Report 2003. Online at http://www.who.int/whr/2003/ en/Facts_and_Figures-en.pdf, 2003.